Clinico-pathological observation of Gaucher disease type I

Authors

DOI:

https://doi.org/10.26641/1997-9665.2024.3.77-81

Keywords:

Gaucher disease, autopsy, microscopic examination

Abstract

Background. Gaucher disease is one of the most common autosomal recessive lysosomal storage diseases which characterize by accumulation of glucosylceramide in the macrophages what is leading to the formation of Gaucher cells in the bone marrow, liver, spleen, brain and other organs with the occurrence of clinical manifestations of varying severity and age of onset. Objective. To describe local and systemic changes in the organs at Gaucher disease type I for optimization of intravital and postmortem diagnostics. Material and methods. A description of autopsy case of Gaucher disease type I. Macroscopic and histological examination were performed using standard processing. Results. In a 24-year-old woman with clinically diagnosed in childhood Gaucher disease type I, who died from liver and kidney failure, pathological examination revealed the formation of characteristic Gaucher cells in the liver with hepatomegaly, fibrosis and reorganization of the liver tissue, in mesenteric lymph nodes, bones, pia mater. The disease was complicated by bilateral hydrothorax, ascites, edema-swelling of the brain tissue, small multiple acute erosions of the stomach and duodenum mucosa with minor acute gastric bleeding, anemia and thrombocytopenia. Conclusion. In the presented observation, in spite of the early diagnostics of Gaucher disease, the patient did not receive appropriate therapy, what led to the development of severe complications and death at young age.

References

  1. Platt FM, d'Azzo A, Davidson BL, Neufeld EF, Tifft CJ. Lysosomal storage diseases. Nat Rev Dis Primers. 2018;4(1):27. doi: 10.1038/s41572-018-0025-4.
  2. Nalysnyk L, Rotella P, Simeone JC, Hamed A, Weinreb N. Gaucher disease epidemiology and natural history: a comprehensive review of the literature. Hematology. 2017;22(2):65-73. doi: 10.1080/10245332.2016.1240391. Epub 2016 Oct 20. PMID: 27762169.
  3. Wang M, Li F, Zhang J, Lu C, Kong W. Global Epidemiology of Gaucher Disease: an Updated Systematic Review and Meta-analysis. J Pediatr Hematol Oncol. 2023;45(4):181-188. doi: 10.1097/MPH.0000000000002506. Epub 2022 Jul 22. PMID: 35867706; PMCID: PMC10115488.
  4. Hruska KS, LaMarca ME, Scott CR, Sidransky E. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat. 2008;29(5):567-583. doi: 10.1002/humu.20676. PMID: 18338393.
  5. Sidransky E. Gaucher disease: insights from a rare Mendelian disorder. Discov Med. 2012;14(77):273-281. PMID: 23114583; PMCID: PMC4141347.
  6. Grabowski GA, Zimran A, Ida H. Gaucher disease types 1 and 3: Phenotypic characterization of large populations from the ICGG Gaucher Registry. Am J Hematol. 2015;90(1):12-18. doi: 10.1002/ajh.24063. PMID: 26096741.
  7. Rosenbloom BE, Weinreb NJ. Gaucher disease: a comprehensive review. Crit Rev Oncog. 2013;18(3):163-175. doi: 10.1615/critrevoncog.2013006060. PMID: 23510062.
  8. Mehta A, Belmatoug N, Bembi B, Deegan P, Elstein D, Göker-Alpan Ö, Lukina E, Mengel E, Nakamura K, Pastores GM, Pérez-López J, Schwartz I, Serratrice C, Szer J, Zimran A, Di Rocco M, Panahloo Z, Kuter DJ, Hughes D. Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians. Mol Genet Metab. 2017;122(3):122-129. doi: 10.1016/j.ymgme.2017.08.002. Epub 2017 Aug 4. PMID: 28847676.
  9. Mistry PK, Cappellini MD, Lukina E, Ozsan H, Mach Pascual S, Rosenbaum H, Helena Solano M, Spigelman Z, Villarrubia J, Watman NP, Massenkeil G. A reappraisal of Gaucher disease-diagnosis and disease management algorithms. Am J Hematol. 2011;86(1):110-115. doi: 10.1002/ajh.21888. PMID: 21080341; PMCID: PMC3058841.
  10. Mistry PK, Sadan S, Yang R, Yee J, Yang M. Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention. Am J Hematol. 2007;82(8):697-701. doi: 10.1002/ajh.20908. PMID: 17492645.
  11. Gonzalez DE, Turkia HB, Lukina EA, Kisinovsky I, Dridi MF, Elstein D, Zahrieh D, Crombez E, Bhirangi K, Barton NW, Zimran A. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study. Am J Hematol. 2013;88(3):166-171. doi: 10.1002/ajh.23381. Epub 2013 Feb 6. PMID: 23386328.
  12. Hughes DA, Gonzalez DE, Lukina EA, Mehta A, Kabra M, Elstein D, Kisinovsky I, Giraldo P, Bavdekar A, Hangartner TN, Wang N, Crombez E, Zimran A. Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials. Am J Hematol. 2015;90(7):584-591. doi: 10.1002/ajh.24012. PMID: 25801797; PMCID: PMC4654249.
  13. Mistry PK, Deegan P, Vellodi A, Cole JA, Yeh M, Weinreb NJ. Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis. Br J Haematol. 2009;147(4):561-570. doi: 10.1111/j.1365-2141.2009.07872.x. Epub 2009 Sep 3. PMID: 19732054; PMCID: PMC2774157.

Published

2024-10-30

How to Cite

Naumova , O., & Potapov , S. (2024). Clinico-pathological observation of Gaucher disease type I. Морфологія / Morphologia / Morfologìâ, 18(3), 77–81. https://doi.org/10.26641/1997-9665.2024.3.77-81

Issue

Section

Статті